Answers are grounded in this paper and cite their sources.
Zika virus (ZIKV), Japanese encephalitis virus (JEV), and dengue virus (DENV) co-circulate in many countries/territories. Our previous publication reported that the antibodies (Abs) induced by ZIKV infection could exacerbate the mortality of JEV-infected mice, bringing challenges to the development of traditional Zika vaccines. Here, we developed two recombinant adenoviruses (Ad5-ZIKV-E WT and Ad5-ZIKV-E mut ) encoding the ZIKV wild-type E protein and an E protein mutant carrying five amino acid substitutions (replaced by alanine) in the bc loop and fusion loop regions of the E protein, respectively. The levels of JEV-cross-reactive or DENV-cross-reactive Ab responses induced by Ad5-ZIKV-E mut immunization in mice are lower than those induced by Ad5-ZIKV-E WT . The level of ZIKV-neutralizing Abs induced by Ad5-ZIKV-E mut is comparable to that elicited by Ad5-ZIKV-E WT . The ability of Abs induced by Ad5-ZIKV-E mut to enhance JEV or DENV infections in vitro is attenuated as compared with that induced by Ad5-ZIKV-E WT . The in vivo protective role of Abs induced by Ad5-ZIKV-E mut is similar to that induced by Ad5-ZIKV-E WT . Mice receiving Ad5-ZIKV-E WT -immune mouse sera exhibited antibody-dependent enhancement (ADE) post-DENV challenge, whereas passively transferred Ad5-ZIKV-E mut -immune mouse sera did not lead to obvious ADE of DENV infection in recipient mice. Notably, maternally acquired Abs did not enhance the mortality of 2-day-old neonates born to Ad5-ZIKV-E mut -immunized mice post-JEV challenge. These results suggest that optimizing the E protein amino acid sequence of ZIKV could significantly reduce the level of cross-reactive Abs to JEV and DENV, and abrogate the ADE of JEV and DENV infections, providing a promising strategy to develop an effective and safe ZIKV vaccine. IMPORTANCE Zika virus (ZIKV), Japanese encephalitis virus (JEV), and dengue virus (DENV) co-circulate in some countries or territories. The results of preliminary animal experiments and clinical cohort studies support that antibodies induced by ZIKV infection can enhance JEV or DENV infection in vitro and in vivo . Therefore, the ZIKV vaccine encoding the wild-type E protein constructed by conventional methods has the antibody-dependent enhancement risk against JEV and DENV infections. In this study, we obtained an E protein mutant by mutating key amino acids in the bc loop and FL sequences of the ZIKV wild-type E protein to alanine. The recombinant adenovirus vaccine based on this E protein mutant is not only effective but also safer in preventing ZIKV infection in the future.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: